Back to Studies

IMPAACT 2039

Phase I/II Study of the Safety, Immunogenicity, Efficacy of HIVconsvX Vaccines in Children Living with HIV

Study Status

In Development

Summary

IMPAACT 2039 is a Phase I/II randomized study of an HIV vaccine regimen in combination with broadly neutralizing antibodies (bNAbs) in children living with HIV. The study will be conducted in two parts. 

  • Preliminary safety and pharmacokinetics (PK) will be evaluated in Part A.
  • Safety, PK, and efficacy in controlling viral replication will be evaluated in Part B.

Approximately 100 children 3-12 years of age are expected to take part in the study at selected sites.

Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...